Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26833776 | 0.85 | NPC1 (0.37) | NPC1LMNAMAPTRECQLRAB9A | |
| SCHEMBL26833748 | 0.84 | LIMK1 (0.33) | CYP1A2CYP17A1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL26833686 | 0.83 | SMN1; SMN2 (0.41) | NPC1LMNAMAPTRECQLRAB9A | |
| SCHEMBL26833754 | 0.83 | CYP1A2 (0.33) | NPC1MAPTRAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL26833755 | 0.82 | GABRP (0.35) | NPC1MAPTRAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL26833772 | 0.81 | NOS1 (0.34) | NPC1MAPTSMN1; SMN2CYP1A2CYP17A1 | |
| SCHEMBL26833778 | 0.80 | NOS1 (0.32) | CYP1A2CYP17A1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL26833747 | 0.80 | IDO1 (0.34) | NPC1MAPTRAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL26833661 | 0.79 | MAPT (0.60) | NPC1LMNAMAPTRECQLRAB9A | |
| SCHEMBL26833489 | 0.78 | CYP1A2 (0.56) | NPC1LMNAMAPTRECQLRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357188-A1 | PHENANTHRENE ORGANIC COMPOUND AND USE THEREOF | WUHAN TIANMA MICROELECTRONICS CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357188-A1 | PHENANTHRENE ORGANIC COMPOUND AND USE THEREOF | WUHAN TIANMA MICROELECTRONICS CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357188-A1 | PHENANTHRENE ORGANIC COMPOUND AND USE THEREOF | AHR, ORAI3, WNT3 | NPC1 2396/4885LMNA 502/4885MAPT 2737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.